Pub Date : 2025-06-13DOI: 10.1186/s41181-025-00350-x
Mario González-Arjona, Lorena Cussó, Luis Alcalá, María Isabel González, Alexandra de Francisco, María Jesús Fernández-Aceñero, Dag Sehlin, Stina Syvänen, Emilio Bouza, Patricia Muñoz, Manuel Desco, Beatriz Salinas
Background
Clostridioides difficile infection (CDI) is a major healthcare challenge that is associated with high morbidity and mortality. Current diagnostic methods are limited in terms of specificity and invasiveness, necessitating novel, non-invasive imaging techniques. In this study, we develop and evaluate an immunoPET radiotracer targeting C. difficile toxin B for in vivo detection of CDI in a murine model.
Results
The monoclonal antibody bezlotoxumab, was radiolabeled with [125I]I for in vitro characterization and with [89Zr]Zr for in vivo PET imaging, resulting in high radiochemical yields (75.36 ± 4.11% for [125I]I and 71.58 ± 8.19% for [89Zr]Zr) and purities (> 99.99% in both cases), with stable binding properties. PET/CT imaging 48 h post-infection in an animal model of CDI (C57BL/6 mice and ribotype 027 strain) demonstrated specific accumulation of [89Zr]Zr-DFO-Beztxab in the colon and cecum of infected mice, thus making it possible to distinguish CDI from dysbiosis without specific C. difficile infection and healthy controls. Findings were confirmed by PET-based quantification and ex vivo biodistribution.
Conclusions
We successfully developed an immunoPET radiotracer targeting toxin B for detection of CDI. Its application in an animal CDI model proved its capacity to detect the source of infection with high specificity, while avoiding confusion with non-specific inflammation.
{"title":"Development of a toxin-selective immunotracer for in vivo detection of Clostridioides difficile infection by immunoPET","authors":"Mario González-Arjona, Lorena Cussó, Luis Alcalá, María Isabel González, Alexandra de Francisco, María Jesús Fernández-Aceñero, Dag Sehlin, Stina Syvänen, Emilio Bouza, Patricia Muñoz, Manuel Desco, Beatriz Salinas","doi":"10.1186/s41181-025-00350-x","DOIUrl":"10.1186/s41181-025-00350-x","url":null,"abstract":"<div><h3>Background</h3><p><i>Clostridioides difficile</i> infection (CDI) is a major healthcare challenge that is associated with high morbidity and mortality. Current diagnostic methods are limited in terms of specificity and invasiveness, necessitating novel, non-invasive imaging techniques. In this study, we develop and evaluate an immunoPET radiotracer targeting <i>C. difficile</i> toxin B for in vivo detection of CDI in a murine model.</p><h3>Results</h3><p>The monoclonal antibody bezlotoxumab, was radiolabeled with [<sup>125</sup>I]I for in vitro characterization and with [<sup>89</sup>Zr]Zr for in vivo PET imaging, resulting in high radiochemical yields (75.36 ± 4.11% for [<sup>125</sup>I]I and 71.58 ± 8.19% for [<sup>89</sup>Zr]Zr) and purities (> 99.99% in both cases), with stable binding properties. PET/CT imaging 48 h post-infection in an animal model of CDI (C57BL/6 mice and ribotype 027 strain) demonstrated specific accumulation of [<sup>89</sup>Zr]Zr-DFO-Beztxab in the colon and cecum of infected mice, thus making it possible to distinguish CDI from dysbiosis without specific <i>C. difficile</i> infection and healthy controls. Findings were confirmed by PET-based quantification and ex vivo biodistribution.</p><h3>Conclusions</h3><p>We successfully developed an immunoPET radiotracer targeting toxin B for detection of CDI. Its application in an animal CDI model proved its capacity to detect the source of infection with high specificity, while avoiding confusion with non-specific inflammation.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12165932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144281875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-10DOI: 10.1186/s41181-025-00352-9
Olivier Fougère, Anne Dencausse, Nicolas Lepareur, Gaetan Van Simaeys, Gilles Doumont, Isabelle Gardin, Elisabeth Renard, Claire Hollenbeck, Coraline De Maeseneire, Nicolas Passon, Olivier Rousseaux, Sarah Catoen
Background
Despite recent therapeutic advances, managing liver cancer remains a significant medical and economic priority for many countries. Patients often present at an advanced stage, preventing them from benefiting from salvage surgery. Consequently, palliative treatments play a crucial role in managing these cancers. Interventional radiology techniques are well-known for providing significant benefits to patients. [90Y]Y-L4-Lipo/Lipiodol® Ultra-Fluid is a novel transarterial radioembolization formulation designed for selective arterial injection to deliver localized radiation treatment of advanced unresectable liver tumors. This study aimed to confirm the stability of [90Y]Y-L4-Lipo/Lipiodol® Ultra-Fluid, investigate its biodistribution in an animal model, and conduct an initial dosimetry evaluation.
Results
Less than 3% of 90Y was released from the [90Y]Y-L4-Lipo/Lipiodol® Ultra-Fluid formulation in human serum. The tumor-to-liver activity ratio (T/NT) expressed in %ID/g tissue at 1 h, 24 h, 3 days, and 6 days (5.50 ± 2.42, 3.28 ± 1.94, 4.89 ± 3.41 and 4.77 ± 1.59, respectively) suggests effective targeting of tumor tissue compared to healthy liver tissue. The extrapolated absorbed doses in Gy in humans to the tumor, normal liver, lung, and red marrow per GBq of [90Y]Y-L4-Lipo/Lipiodol® Ultra-Fluid administered were 54.3, 16.2, 0.69 and 0.89, for males, and 54.3, 22.3, 0.84 and 0.89, respectively, for females.
Conclusion
With good in vitro stability at low activity lasting at least 3 half-lives and a T/NT ratio of 4 in vivo, [90Y]Y-L4-Lipo/Lipiodol® Ultra-Fluid is confirmed as a valid candidate treatment for transarterial radioembolization of hepatocellular carcinoma. High activity stability in both in vitro and in vivo studies is needed to complete the formulation’s safety profile.
背景：尽管最近的治疗取得了进展，但对许多国家来说，肝癌的治疗仍然是一个重要的医疗和经济重点。患者往往出现在晚期，阻止他们从抢救手术中获益。因此，姑息治疗在治疗这些癌症中起着至关重要的作用。介入放射学技术为患者提供了显著的益处。[90Y]Y-L4-Lipo/Lipiodol®Ultra-Fluid是一种新型经动脉放射栓塞制剂，用于选择性动脉注射，为晚期不可切除的肝脏肿瘤提供局部放射治疗。本研究旨在证实[90Y]Y-L4-Lipo/Lipiodol®Ultra-Fluid的稳定性，研究其在动物模型中的生物分布，并进行初步剂量学评价。结果：[90Y]Y-L4-Lipo/Lipiodol®超流体制剂在人血清中释放的90Y不到3%。1 h、24 h、3 d、6 d %ID/g组织中表达的瘤肝活性比（T/NT）分别为5.50±2.42、3.28±1.94、4.89±3.41和4.77±1.59，表明与健康肝组织相比，肿瘤组织具有有效的靶向性。[90Y]Y-L4-Lipo/Lipiodol®Ultra-Fluid每GBq对人体肿瘤、正常肝脏、肺和红骨髓的吸收剂量外推为男性54.3、16.2、0.69和0.89，女性54.3、22.3、0.84和0.89。结论：[90Y]Y-L4-Lipo/Lipiodol®Ultra-Fluid在低活性下具有良好的体外稳定性，至少持续3个半衰期，体内T/NT比值为4，被证实是肝细胞癌经动脉放射栓塞治疗的有效候选治疗方法。需要在体外和体内研究中具有高活性稳定性，以完成配方的安全性。
{"title":"[90Y]Y-L4-Lipo/ ethyl esters of Iodized fatty acids of poppy seed oil (lipiodol® ultra-fluid), a new TARE formulation, designed from a lipophilic ligand for stability and safety","authors":"Olivier Fougère, Anne Dencausse, Nicolas Lepareur, Gaetan Van Simaeys, Gilles Doumont, Isabelle Gardin, Elisabeth Renard, Claire Hollenbeck, Coraline De Maeseneire, Nicolas Passon, Olivier Rousseaux, Sarah Catoen","doi":"10.1186/s41181-025-00352-9","DOIUrl":"10.1186/s41181-025-00352-9","url":null,"abstract":"<div><h3>Background</h3><p>Despite recent therapeutic advances, managing liver cancer remains a significant medical and economic priority for many countries. Patients often present at an advanced stage, preventing them from benefiting from salvage surgery. Consequently, palliative treatments play a crucial role in managing these cancers. Interventional radiology techniques are well-known for providing significant benefits to patients. [<sup>90</sup>Y]Y-L4-Lipo/Lipiodol<sup>®</sup> Ultra-Fluid is a novel transarterial radioembolization formulation designed for selective arterial injection to deliver localized radiation treatment of advanced unresectable liver tumors. This study aimed to confirm the stability of [<sup>90</sup>Y]Y-L4-Lipo/Lipiodol<sup>®</sup> Ultra-Fluid, investigate its biodistribution in an animal model, and conduct an initial dosimetry evaluation.</p><h3>Results</h3><p>Less than 3% of <sup>90</sup>Y was released from the [<sup>90</sup>Y]Y-L4-Lipo/Lipiodol<sup>®</sup> Ultra-Fluid formulation in human serum. The tumor-to-liver activity ratio (T/NT) expressed in %ID/g tissue at 1 h, 24 h, 3 days, and 6 days (5.50 ± 2.42, 3.28 ± 1.94, 4.89 ± 3.41 and 4.77 ± 1.59, respectively) suggests effective targeting of tumor tissue compared to healthy liver tissue. The extrapolated absorbed doses in Gy in humans to the tumor, normal liver, lung, and red marrow per GBq of [<sup>90</sup>Y]Y-L4-Lipo/Lipiodol<sup>®</sup> Ultra-Fluid administered were 54.3, 16.2, 0.69 and 0.89, for males, and 54.3, 22.3, 0.84 and 0.89, respectively, for females.</p><h3>Conclusion</h3><p>With good in vitro stability at low activity lasting at least 3 half-lives and a T/NT ratio of 4 in vivo, [<sup>90</sup>Y]Y-L4-Lipo/Lipiodol<sup>®</sup> Ultra-Fluid is confirmed as a valid candidate treatment for transarterial radioembolization of hepatocellular carcinoma. High activity stability in both in vitro and in vivo studies is needed to complete the formulation’s safety profile.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12151968/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-02DOI: 10.1186/s41181-025-00351-w
S. Spreckelmeyer, J. Dasilva, C. Decristoforo, R. H. Mach, J. Passchier, G. Carlucci, M. Al Qahtani, A. Duatti, B. T. Cornelissen, J. Engle, A. Denkova, J. J. M. A. Hendrikx, Y. Seimbille, X. Yang, H. Jia, M-R. Zhang, M. Yang, L. Perk, P. Caravan, P. Laverman, Z. Cheng, C. Hoehr, T. Sakr, J. R. Zeevaart
{"title":"Correction: Highlight selection of radiochemistry and radiopharmacy developments by editorial board","authors":"S. Spreckelmeyer, J. Dasilva, C. Decristoforo, R. H. Mach, J. Passchier, G. Carlucci, M. Al Qahtani, A. Duatti, B. T. Cornelissen, J. Engle, A. Denkova, J. J. M. A. Hendrikx, Y. Seimbille, X. Yang, H. Jia, M-R. Zhang, M. Yang, L. Perk, P. Caravan, P. Laverman, Z. Cheng, C. Hoehr, T. Sakr, J. R. Zeevaart","doi":"10.1186/s41181-025-00351-w","DOIUrl":"10.1186/s41181-025-00351-w","url":null,"abstract":"","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12130380/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144197959","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-30DOI: 10.1186/s41181-025-00347-6
Anzhelika Vorobyeva, Moeen-ud Din, Alexey Schulga, Elena Konovalova, Ayman Abouzayed, Olga Bragina, Ruonan Li, Torbjörn Gräslund, Sergey M. Deyev, Maryam Oroujeni
Background
Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein, which is overexpressed in several types of malignancies. Designed ankyrin repeat protein (DARPin) Ec1 is a 19 kDa engineered scaffold protein that binds with high affinity to EpCAM. Radiolabelled Ec1 might be used as a companion diagnostic for the selection of patients for personalized therapy. This study aimed to investigate the influence of different radiometal-chelator complexes on the biodistribution and imaging contrast of 68Ga-labelled Ec1. To investigate this, two macrocyclic chelators, 1,4,7-triazacyclononane-N,N,N-triacetic acid (NOTA) and 1-(1,3-carboxypropyl)-1,4,7-triazacyclononane-4,7-diacetic acid (NODAGA) were conjugated to the C-terminus of the Ec1. The previously developed DARPin Ec1 conjugated to 1,4,7,10-tetraazacylododecane-1,4,7,10-tetraacetic acid (DOTA) was used as a comparator.
Results
All Ec1 variants were successfully labelled with 68Ga. The use of NOTA and NODAGA provided twice higher radiochemical yield and improved label stability compared to DOTA. All labelled Ec1 variants bound to the EpCAM-expressing cells with nanomolar affinity and preserved targeting specificity in vitro and in vivo. Biodistribution studies in mice bearing EpCAM-expressing SKOV-3 xenografts showed that [68Ga]Ga-Ec1-NOTA had lower uptake in most normal organs while maintaining tumor uptake. Among all variants, [68Ga]Ga-Ec1-NOTA showed the lowest liver uptake, with no significant differences in tumor uptake. Additionally, [68Ga]Ga-Ec1-NOTA provided the highest tumor-to-blood ratio compared to [68Ga]Ga-Ec1-DOTA and [68Ga]Ga-Ec1-NODAGA.
Conclusion
[68Ga]Ga-Ec1-NOTA is the preferred radioconjugate for PET imaging of EpCAM expression.
{"title":"Selection of the optimal chelator for labeling of DARPin Ec1 with gallium-68 for PET imaging of EpCAM expression","authors":"Anzhelika Vorobyeva, Moeen-ud Din, Alexey Schulga, Elena Konovalova, Ayman Abouzayed, Olga Bragina, Ruonan Li, Torbjörn Gräslund, Sergey M. Deyev, Maryam Oroujeni","doi":"10.1186/s41181-025-00347-6","DOIUrl":"10.1186/s41181-025-00347-6","url":null,"abstract":"<div><h3>Background</h3><p>Epithelial cell adhesion molecule (EpCAM) is a transmembrane glycoprotein, which is overexpressed in several types of malignancies. Designed ankyrin repeat protein (DARPin) Ec1 is a 19 kDa engineered scaffold protein that binds with high affinity to EpCAM. Radiolabelled Ec1 might be used as a companion diagnostic for the selection of patients for personalized therapy. This study aimed to investigate the influence of different radiometal-chelator complexes on the biodistribution and imaging contrast of <sup>68</sup>Ga-labelled Ec1. To investigate this, two macrocyclic chelators, 1,4,7-triazacyclononane-N,N,N-triacetic acid (NOTA) and 1-(1,3-carboxypropyl)-1,4,7-triazacyclononane-4,7-diacetic acid (NODAGA) were conjugated to the C-terminus of the Ec1. The previously developed DARPin Ec1 conjugated to 1,4,7,10-tetraazacylododecane-1,4,7,10-tetraacetic acid (DOTA) was used as a comparator.</p><h3>Results</h3><p>All Ec1 variants were successfully labelled with <sup>68</sup>Ga. The use of NOTA and NODAGA provided twice higher radiochemical yield and improved label stability compared to DOTA. All labelled Ec1 variants bound to the EpCAM-expressing cells with nanomolar affinity and preserved targeting specificity in vitro and in vivo. Biodistribution studies in mice bearing EpCAM-expressing SKOV-3 xenografts showed that [<sup>68</sup>Ga]Ga-Ec1-NOTA had lower uptake in most normal organs while maintaining tumor uptake. Among all variants, [<sup>68</sup>Ga]Ga-Ec1-NOTA showed the lowest liver uptake, with no significant differences in tumor uptake. Additionally, [<sup>68</sup>Ga]Ga-Ec1-NOTA provided the highest tumor-to-blood ratio compared to [<sup>68</sup>Ga]Ga-Ec1-DOTA and [<sup>68</sup>Ga]Ga-Ec1-NODAGA.</p><h3>Conclusion</h3><p>[<sup>68</sup>Ga]Ga-Ec1-NOTA is the preferred radioconjugate for PET imaging of EpCAM expression.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125460/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-30DOI: 10.1186/s41181-025-00346-7
Fahimeh Bayat
Background
Radiolabeling is a technique that involves attaching radioactive isotopes to molecules, allowing for their tracking and analysis in biological systems. Radiolabeled d-glucose and its derivatives have a very prominent role in exploring metabolic pathways, the enzymatic system, and measuring the flow of the metabolites through biochemical reactions, as accumulation or deficiency of metabolites occurs along with metabolic disorders. Glucose as the main source of energy in the body is involved in different metabolic pathways like glycolysis, pentose phosphate pathway, and tricarboxylic acid cycle. Various derivatives of glucose are labeled at different positions by 14C and 3H. The aim of this review is to summarize some of the most significant aspects of the use of different radiolabeled d-glucose, 2-deoxy-d-glucose, and methyl-α-d-glucopyranoside.
Main body
This review focuses on the application of radiolabeled glucose derivatives in studying glucose transport systems, metabolic pathways, enzyme activity, and glucose utilization across various tissues. It highlights their role in understanding disease mechanisms in diabetes, cancer, heart failure, and metabolic disorders, and the impact of pharmacological agents and environmental pollutants.
Conclusion
In conclusion, radiolabeled glucose derivatives are invaluable tools for studying glucose metabolism across various tissues and organs. They provide critical insights into metabolic dysfunctions, disease mechanisms, and therapeutic interventions, aiding in the development of targeted treatments for conditions like diabetes, cancer, and cardiovascular diseases.
背景：放射性标记是一种将放射性同位素附着到分子上的技术，允许在生物系统中对其进行跟踪和分析。放射性标记的d -葡萄糖及其衍生物在探索代谢途径、酶系统和通过生化反应测量代谢物流量方面具有非常突出的作用，因为代谢物的积累或缺乏伴随着代谢紊乱而发生。葡萄糖作为机体的主要能量来源，参与糖酵解、戊糖磷酸途径、三羧酸循环等多种代谢途径。葡萄糖的各种衍生物在不同位置用14C和3H标记。本文综述了不同放射性标记的d -葡萄糖、2-脱氧d -葡萄糖和甲基-α- d -葡萄糖苷的一些最重要的方面。正文：本文综述了放射性标记葡萄糖衍生物在研究葡萄糖转运系统、代谢途径、酶活性和葡萄糖在不同组织中的利用方面的应用。它强调了它们在理解糖尿病、癌症、心力衰竭和代谢紊乱的疾病机制以及药理药物和环境污染物的影响方面的作用。结论：放射性标记葡萄糖衍生物是研究不同组织和器官中葡萄糖代谢的宝贵工具。它们为代谢功能障碍、疾病机制和治疗干预提供了重要见解，有助于开发针对糖尿病、癌症和心血管疾病等疾病的靶向治疗方法。
{"title":"d-Glucose and its derivatives labeled with radioactive carbon and hydrogen: key tools for investigating biological processes and molecular mechanisms","authors":"Fahimeh Bayat","doi":"10.1186/s41181-025-00346-7","DOIUrl":"10.1186/s41181-025-00346-7","url":null,"abstract":"<div><h3>Background</h3><p>Radiolabeling is a technique that involves attaching radioactive isotopes to molecules, allowing for their tracking and analysis in biological systems. Radiolabeled <span>d</span>-glucose and its derivatives have a very prominent role in exploring metabolic pathways, the enzymatic system, and measuring the flow of the metabolites through biochemical reactions, as accumulation or deficiency of metabolites occurs along with metabolic disorders. Glucose as the main source of energy in the body is involved in different metabolic pathways like glycolysis, pentose phosphate pathway, and tricarboxylic acid cycle. Various derivatives of glucose are labeled at different positions by <sup>14</sup>C and <sup>3</sup>H. The aim of this review is to summarize some of the most significant aspects of the use of different radiolabeled <span>d</span>-glucose, 2-deoxy-<span>d</span>-glucose, and methyl-<i>α</i>-<span>d</span>-glucopyranoside.</p><h3>Main body</h3><p>This review focuses on the application of radiolabeled glucose derivatives in studying glucose transport systems, metabolic pathways, enzyme activity, and glucose utilization across various tissues. It highlights their role in understanding disease mechanisms in diabetes, cancer, heart failure, and metabolic disorders, and the impact of pharmacological agents and environmental pollutants.</p><h3>Conclusion</h3><p>In conclusion, radiolabeled glucose derivatives are invaluable tools for studying glucose metabolism across various tissues and organs. They provide critical insights into metabolic dysfunctions, disease mechanisms, and therapeutic interventions, aiding in the development of targeted treatments for conditions like diabetes, cancer, and cardiovascular diseases.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12125467/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144186173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-19DOI: 10.1186/s41181-025-00349-4
Subhani M. Okarvi, Yousef Maliki
Background
Simultaneous targeting of RGD and FA receptors on breast carcinoma could improve the diagnostic outcome of breast cancer patients. In this study, we have designed and synthesized an FA-RGD heteromeric targeting vector, with both RGD and FA motifs, in one single molecule for positron emission tomography (PET) diagnostic imaging of breast carcinoma.
Results
Aoa-FA-RGD peptide conjugate was radiolabeled efficiently with [18F]FDG, resulting in high labeling efficiency (≥ 85%). The in vitro stability of the radiotracer in human plasma was found to be high. The Aoa-FA-RGD peptide conjugate showed the nanomolar affinity (≤ 51 nM) to the TNBC MDA-MB-231 cell line. In the MDA-MB-231 xenografts model, [18F]FDG-Aoa-FA-RGD peptide conjugate exhibited efficient clearance from the blood and excretion predominantly by the renal pathway (~ 56% ID), possibly due to its hydrophilic nature. A rapid accumulation of 3.30% ID/g in the TNBC MDA-MB-231 tumors was observed at 45 min p.i. Whereas a low accumulation of radioactivity was seen in the normal organs, including the heart, lungs, liver, stomach, spleen, intestines, and kidneys (< 4% ID/g). The receptor specificity of the radiotracer was confirmed by the receptor-blocking assay. A rapid and efficient tumor targeting, together with the favorable pharmacokinetics, highlights the tumor-targeting potential of the radiofluroconjugate. Furthermore, PET imaging provided sufficient visualization of MDA-MB-231 tumors in mice.
Conclusions
Our findings suggest that the [18F]FDG-labeled FA-RGD peptide conjugate can be a useful agent for the efficient targeting of TNBC cells. This study suggests the potential of this innovative heteromeric targeting agent for rapid and efficient targeting of tumors and merits further advancement.
背景RGD和FA受体同时靶向乳腺癌可改善乳腺癌患者的诊断结果。在这项研究中，我们设计并合成了一个FA-RGD异质靶向载体，同时具有RGD和FA基序，用于乳腺癌正电子发射断层扫描（PET）诊断成像。结果[18F]FDG对saoa - fa - rgd肽偶联物进行了有效的放射性标记，标记效率高（≥85%）。该放射性示踪剂在人血浆中的体外稳定性较高。Aoa-FA-RGD肽偶联物对TNBC MDA-MB-231细胞系具有纳米摩尔亲和力（≤51 nM）。在MDA-MB-231异种移植物模型中，[18F]FDG-Aoa-FA-RGD肽偶联物表现出有效的血液清除和主要通过肾途径排泄（~ 56% ID），可能是由于其亲水性。在45 min p.i时，TNBC MDA-MB-231肿瘤的放射性迅速积累为3.30% ID/g。而在正常器官，包括心、肺、肝、胃、脾、肠和肾中，放射性积累较低（4% ID/g）。受体阻断试验证实了放射性示踪剂的受体特异性。快速有效的肿瘤靶向，加上良好的药代动力学，突出了放射性氟偶联物的肿瘤靶向潜力。此外，PET成像提供了小鼠MDA-MB-231肿瘤的充分可视化。结论[18F] fdg标记的FA-RGD肽偶联物可能是一种有效靶向TNBC细胞的有效药物。这项研究表明，这种创新的异源靶向药物具有快速有效靶向肿瘤的潜力，值得进一步发展。
{"title":"Preparation and preclinical evaluation of 18F-labeled folate-RGD peptide conjugate for PET imaging of triple-negative breast carcinoma","authors":"Subhani M. Okarvi, Yousef Maliki","doi":"10.1186/s41181-025-00349-4","DOIUrl":"10.1186/s41181-025-00349-4","url":null,"abstract":"<div><h3>Background</h3><p>Simultaneous targeting of RGD and FA receptors on breast carcinoma could improve the diagnostic outcome of breast cancer patients. In this study, we have designed and synthesized an FA-RGD heteromeric targeting vector, with both RGD and FA motifs, in one single molecule for positron emission tomography (PET) diagnostic imaging of breast carcinoma.</p><h3>Results</h3><p>Aoa-FA-RGD peptide conjugate was radiolabeled efficiently with [<sup>18</sup>F]FDG, resulting in high labeling efficiency (≥ 85%). The in vitro stability of the radiotracer in human plasma was found to be high. The Aoa-FA-RGD peptide conjugate showed the nanomolar affinity (≤ 51 nM) to the TNBC MDA-MB-231 cell line. In the MDA-MB-231 xenografts model, [<sup>18</sup>F]FDG-Aoa-FA-RGD peptide conjugate exhibited efficient clearance from the blood and excretion predominantly by the renal pathway (~ 56% ID), possibly due to its hydrophilic nature. A rapid accumulation of 3.30% ID/g in the TNBC MDA-MB-231 tumors was observed at 45 min p.i. Whereas a low accumulation of radioactivity was seen in the normal organs, including the heart, lungs, liver, stomach, spleen, intestines, and kidneys (< 4% ID/g). The receptor specificity of the radiotracer was confirmed by the receptor-blocking assay. A rapid and efficient tumor targeting, together with the favorable pharmacokinetics, highlights the tumor-targeting potential of the radiofluroconjugate. Furthermore, PET imaging provided sufficient visualization of MDA-MB-231 tumors in mice.</p><h3>Conclusions</h3><p>Our findings suggest that the [<sup>18</sup>F]FDG-labeled FA-RGD peptide conjugate can be a useful agent for the efficient targeting of TNBC cells. This study suggests the potential of this innovative heteromeric targeting agent for rapid and efficient targeting of tumors and merits further advancement.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-025-00349-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-17DOI: 10.1186/s41181-025-00342-x
Julia Greiser, Beatrice Engert, Roman Föll, Robert Klopfleisch, Rebecca Steens, Marion Hecht, Martin Freesmeyer
Background
N,1,4-Tri(4-ethoxy-2-hydroxybenzyl)-1,4-diazepan-6-amine (TEoS-DAZA), a novel radiopharmaceutical precursor for a liver-specific 68Ga-based diagnostic radiopharmaceutical, was tested for toxicity in rats to ensure its safe applicability and to fulfil the preclinical requirements in preparation of a clinical study. The study was performed according to EMA draft Guideline on the non-clinical requirements for radiopharmaceuticals, as well as to the so-called microdosing approach of the ICH guideline M3 (R2).
Results
This randomized study was conducted using Wistar rats. The test item was administered intravenously at three different dose levels, the vehicle solution was administered to a separate group as control. Toxicity assessment included a 24 h observation period in three dose groups, and a 14-day recovery period in the high dose group. Animals were monitored regarding clinical behaviour, bodyweight, food and water consumption, additionally undergoing modified IRWIN, grip-strength and beam-walking tests. Following euthanisation, extensive haematological and clinical biochemical parameters were analysed. Necropsy and histopathology were performed. There was no evidence to any test-item related adversities at any dose level. No delayed effects were identified in any animal at the end of the recovery phase. Some small, albeit significant changes in haematology and clinical biochemistry could not be related to the test item administration. The NOAEL of TEoS-DAZA was determined at 1.4 mg/kg bodyweight.
Conclusions
Administration of a thousandfold clinical dose of TEoS-DAZA in rats did not cause any observable adverse events. An injectable solution of [68Ga]Ga-TEoS-DAZA containing 100 µg of the precursor is safe for clinical application to humans from the pharmacological point of view. Subsequent dosimetry studies need to be undertaken to reveal any radiation related toxicity.
{"title":"Toxicity study of TEoS-DAZA, a chemical precursor for functional liver imaging with PET/CT","authors":"Julia Greiser, Beatrice Engert, Roman Föll, Robert Klopfleisch, Rebecca Steens, Marion Hecht, Martin Freesmeyer","doi":"10.1186/s41181-025-00342-x","DOIUrl":"10.1186/s41181-025-00342-x","url":null,"abstract":"<div><h3>Background</h3><p><i>N</i>,1,4-Tri(4-ethoxy-2-hydroxybenzyl)-1,4-diazepan-6-amine (TEoS-DAZA), a novel radiopharmaceutical precursor for a liver-specific <sup>68</sup>Ga-based diagnostic radiopharmaceutical, was tested for toxicity in rats to ensure its safe applicability and to fulfil the preclinical requirements in preparation of a clinical study. The study was performed according to EMA draft Guideline on the non-clinical requirements for radiopharmaceuticals, as well as to the so-called microdosing approach of the ICH guideline M3 (R2).</p><h3>Results</h3><p>This randomized study was conducted using Wistar rats. The test item was administered intravenously at three different dose levels, the vehicle solution was administered to a separate group as control. Toxicity assessment included a 24 h observation period in three dose groups, and a 14-day recovery period in the high dose group. Animals were monitored regarding clinical behaviour, bodyweight, food and water consumption, additionally undergoing modified IRWIN, grip-strength and beam-walking tests. Following euthanisation, extensive haematological and clinical biochemical parameters were analysed. Necropsy and histopathology were performed. There was no evidence to any test-item related adversities at any dose level. No delayed effects were identified in any animal at the end of the recovery phase. Some small, albeit significant changes in haematology and clinical biochemistry could not be related to the test item administration. The NOAEL of TEoS-DAZA was determined at 1.4 mg/kg bodyweight.</p><h3>Conclusions</h3><p>Administration of a thousandfold clinical dose of TEoS-DAZA in rats did not cause any observable adverse events. An injectable solution of [<sup>68</sup>Ga]Ga-TEoS-DAZA containing 100 µg of the precursor is safe for clinical application to humans from the pharmacological point of view. Subsequent dosimetry studies need to be undertaken to reveal any radiation related toxicity.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-025-00342-x","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144073555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-13DOI: 10.1186/s41181-025-00341-y
Arnaud Deschavannes, Kazuma Terashi, Marie Piquemal, Catherine Rioufol, Anthony Clotagatide
Background
The increasing use of [⁶⁸Ga]Ga-based radiopharmaceuticals in PET imaging, requires efficient quality control procedures. The standard r-TLC method for verifying [⁶⁸Ga]Ga-EDOTREOTIDE (Somakit-TOC®) radiochemical purity (RCP) is time-consuming, creating workflow challenges in radiopharmacies. This study evaluates an optimized r-TLC method with a reduced migration distance (4 cm vs. 9 cm) to improve efficiency while maintaining analytical reliability. Tests for specificity, accuracy and robustness were performed using ITLC-SG – Acetate and ITLC-SG – Citrate systems. Additionally, migration time was analyzed to evaluate whether the alternative method could offer added benefits.
Results
The mean Rs for ITLC-SG – Acetate at 4 cm was 2.43 ± 0.28, while for ITLC-SG – Citrate with added [⁶⁸Ga]GaCl₃ was 5.58 ± 0.23, both exceeding the threshold of 1.5. The mean RCP at 4 cm was 98.90% ± 0.25%, and 99.21% ± 0.19% at 9 cm, with [⁶⁸Ga]Ga-uncomplexed remaining within acceptable limits. No [⁶⁸Ga]GaCl₃ was detected. The coefficient of variation (CV) for RCP between methods was < 2% (0.22%). Operator-based analysis yielded a mean Rs of 3.95 ± 0.06 (CV = 1.52%) and a mean [⁶⁸Ga]Ga-EDOTREOTIDE percentage of 99.60% ± 0.03% (CV = 0.03%). Migration times were significantly reduced with the alternative method (85% reduction).
Conclusion
Shortening the migration distance in r-TLC did not compromise specificity, accuracy or robustness while significantly reducing analysis time. The proposed method enhances PET radiopharmaceutical workflows, allowing faster patient dose preparation without quality loss. This approach could be investigated to other [68Ga]Ga-labeled compounds, supporting improved clinical and research applications in nuclear medicine.
{"title":"Optimization of radiochemical purity assessment for [68Ga]Ga-EDOTREOTIDE (Somakit-TOC®): a shortened r-TLC method for improved PET radiopharmaceutical workflow","authors":"Arnaud Deschavannes, Kazuma Terashi, Marie Piquemal, Catherine Rioufol, Anthony Clotagatide","doi":"10.1186/s41181-025-00341-y","DOIUrl":"10.1186/s41181-025-00341-y","url":null,"abstract":"<div><h3>Background</h3><p>The increasing use of [⁶⁸Ga]Ga-based radiopharmaceuticals in PET imaging, requires efficient quality control procedures. The standard r-TLC method for verifying [⁶⁸Ga]Ga-EDOTREOTIDE (Somakit-TOC<sup>®</sup>) radiochemical purity (RCP) is time-consuming, creating workflow challenges in radiopharmacies. This study evaluates an optimized r-TLC method with a reduced migration distance (4 cm vs. 9 cm) to improve efficiency while maintaining analytical reliability. Tests for specificity, accuracy and robustness were performed using ITLC-SG – Acetate and ITLC-SG – Citrate systems. Additionally, migration time was analyzed to evaluate whether the alternative method could offer added benefits.</p><h3>Results</h3><p>The mean Rs for ITLC-SG – Acetate at 4 cm was 2.43 ± 0.28, while for ITLC-SG – Citrate with added [⁶⁸Ga]GaCl₃ was 5.58 ± 0.23, both exceeding the threshold of 1.5. The mean RCP at 4 cm was 98.90% ± 0.25%, and 99.21% ± 0.19% at 9 cm, with [⁶⁸Ga]Ga-uncomplexed remaining within acceptable limits. No [⁶⁸Ga]GaCl₃ was detected. The coefficient of variation (CV) for RCP between methods was < 2% (0.22%). Operator-based analysis yielded a mean Rs of 3.95 ± 0.06 (CV = 1.52%) and a mean [⁶⁸Ga]Ga-EDOTREOTIDE percentage of 99.60% ± 0.03% (CV = 0.03%). Migration times were significantly reduced with the alternative method (85% reduction).</p><h3>Conclusion</h3><p>Shortening the migration distance in r-TLC did not compromise specificity, accuracy or robustness while significantly reducing analysis time. The proposed method enhances PET radiopharmaceutical workflows, allowing faster patient dose preparation without quality loss. This approach could be investigated to other [<sup>68</sup>Ga]Ga-labeled compounds, supporting improved clinical and research applications in nuclear medicine.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-025-00341-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-13DOI: 10.1186/s41181-025-00345-8
Xiyan Rui, Yuzhou Ding, Nailian Zhang, Xinran Zhao, Chie Seki, Tomoteru Yamasaki, Masayuki Fujinaga, Ming-Rong Zhang, Jun Qian, Bin Ji, Rong Zhou
Background
Colony-stimulating factor 1 receptor (CSF1R) is a promising imaging biomarker for neuroinflammation and tumor-associated macrophages. However, existing positron emission tomography (PET) tracers for CSF1R imaging often suffer from limited specificity or sensitivity.
Results
We have performed 11C-labeled radiosynthesis of compound FJRD (3-((2-amino-5-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl)ethynyl)-N-(4-methoxyphenyl)-4-methylbenzamide), which exhibits excellent affinity for CSF1R, and evaluated its in vivo and in vitro binding properties. PET images of [11C]FJRD show low brain uptake and specific binding in the living organs, except the kidneys in both normal mice and rats. In vitro autoradiographs demonstrate high levels of specific binding in all investigated organs, including the brain, spleen, liver, kidneys and lungs, when self-blocking was used. The addition of CPPC partially blocked in vitro [11C]FJRD binding in these organs, with blocking effects ranging from 9 to 67%. In contrast, the other two CSF1R inhibitors, GW2580 and BLZ945, showed minimal blocking effects, suggesting unignorable off-target binding in these organs. Furthermore, specific binding of [11C]CPPC and [11C]GW2580 was faint in the mouse organs, with [11C]CPPC demonstrating detectable binding only in the spleen.
Conclusions
These results suggest that [11C]FJRD is a potential CSF1R-PET tracer for more sensitive detection of CSF1R, compared to [11C]CPPC and [11C]GW2580. However, the high level off-target binding necessitates further improvements in specificity for CSF1R imaging.
{"title":"Evaluation of in vivo and in vitro binding property of a novel candidate PET tracer for CSF1R imaging and comparison with two currently-used CSF1R-PET tracers","authors":"Xiyan Rui, Yuzhou Ding, Nailian Zhang, Xinran Zhao, Chie Seki, Tomoteru Yamasaki, Masayuki Fujinaga, Ming-Rong Zhang, Jun Qian, Bin Ji, Rong Zhou","doi":"10.1186/s41181-025-00345-8","DOIUrl":"10.1186/s41181-025-00345-8","url":null,"abstract":"<div><h3>Background</h3><p>Colony-stimulating factor 1 receptor (CSF1R) is a promising imaging biomarker for neuroinflammation and tumor-associated macrophages. However, existing positron emission tomography (PET) tracers for CSF1R imaging often suffer from limited specificity or sensitivity.</p><h3>Results</h3><p>We have performed <sup>11</sup>C-labeled radiosynthesis of compound FJRD (3-((2-amino-5-(1-methyl-1<i>H</i>-pyrazol-4-yl)pyridin-3-yl)ethynyl)-<i>N</i>-(4-methoxyphenyl)-4-methylbenzamide), which exhibits excellent affinity for CSF1R, and evaluated its in vivo and in vitro binding properties. PET images of [<sup>11</sup>C]FJRD show low brain uptake and specific binding in the living organs, except the kidneys in both normal mice and rats. In vitro autoradiographs demonstrate high levels of specific binding in all investigated organs, including the brain, spleen, liver, kidneys and lungs, when self-blocking was used. The addition of CPPC partially blocked in vitro [<sup>11</sup>C]FJRD binding in these organs, with blocking effects ranging from 9 to 67%. In contrast, the other two CSF1R inhibitors, GW2580 and BLZ945, showed minimal blocking effects, suggesting unignorable off-target binding in these organs. Furthermore, specific binding of [<sup>11</sup>C]CPPC and [<sup>11</sup>C]GW2580 was faint in the mouse organs, with [<sup>11</sup>C]CPPC demonstrating detectable binding only in the spleen.</p><h3>Conclusions</h3><p>These results suggest that [<sup>11</sup>C]FJRD is a potential CSF1R-PET tracer for more sensitive detection of CSF1R, compared to [<sup>11</sup>C]CPPC and [<sup>11</sup>C]GW2580. However, the high level off-target binding necessitates further improvements in specificity for CSF1R imaging.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-025-00345-8","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143944178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-05-04DOI: 10.1186/s41181-025-00343-w
Ammar Alfteimi, Yi Zhao, Ulf Lützen, Alexander Helm, Michael Jüptner, Maaz Zuhayra
Background
[18F]Fallypride PET has been used to study D2/3 receptor occupancy and density in neuropsychiatric disorders including Huntington’s disease (HD) and aging in humans. Nevertheless, the various synthetic methods including those provided by commercial synthesizers for [18F]fallypride exhibit a disadvantage concerning the necessity of using a HPLC purification step, which causes difficulties in the automation, leads to long synthesis times and moderate yields. Therefore utilizing the purification step by SPE cartridges is considered highly desirable for future commercialization of radiopharmaceutical cassettes. In our lab we have developed a simplified reliable automatic Radiosynthesis of [18F]fallypride by using SPE cartridges for the purification step without the need of HPLC.
Results
A simplified Radiosynthesis of [18F]fallypride has been developed without the use of HPLC for both a commercial cassette based synthesis system (AllinOne (AiO) system, Trasis, Belgium) and a research synthesis module with fixed tubing (RNplus, Synthra, Germany). The cleaning step involves a serial combination of several SPE cartridges. The synthesis time was shortened by 44% compared to synthesis using HPLC. At the same time the not decay corrected yield increases from 44 to 59% by using TBAHCO3 as phase transfer catalysts and from 17 to 31% for the synthesis with K2CO3/Kryptofix-[2.2.2] compared to synthesis using HPLC. The Radiochemical purity was always > 98% and all quality control parameters (e.g. sterility, endotoxin, stability and Radiochemical purity) conformed with requirements of the European Pharmacopoeia.
Conclusions
A GMP compliant automatic synthesis of [18F]fallypride including purification using simple solid phase extraction cartridges instead of HPLC was developed and evaluated. The implementation of the simplified synthesis in both used commercial modules allows efficient and reproducible Radiosynthesis of [18F]fallypride and leads to short synthesis times and high radiochemical yields with high radiochemical purity.
{"title":"GMP compliant simplified fast and high yielding automated synthesis of [18F]fallypride without the need of HPLC purification","authors":"Ammar Alfteimi, Yi Zhao, Ulf Lützen, Alexander Helm, Michael Jüptner, Maaz Zuhayra","doi":"10.1186/s41181-025-00343-w","DOIUrl":"10.1186/s41181-025-00343-w","url":null,"abstract":"<div><h3>Background</h3><p>[<sup>18</sup>F]Fallypride PET has been used to study D2/3 receptor occupancy and density in neuropsychiatric disorders including Huntington’s disease (HD) and aging in humans. Nevertheless, the various synthetic methods including those provided by commercial synthesizers for [<sup>18</sup>F]fallypride exhibit a disadvantage concerning the necessity of using a HPLC purification step, which causes difficulties in the automation, leads to long synthesis times and moderate yields. Therefore utilizing the purification step by SPE cartridges is considered highly desirable for future commercialization of radiopharmaceutical cassettes. In our lab we have developed a simplified reliable automatic Radiosynthesis of [<sup>18</sup>F]fallypride by using SPE cartridges for the purification step without the need of HPLC.</p><h3>Results</h3><p>A simplified Radiosynthesis of [<sup>18</sup>F]fallypride has been developed without the use of HPLC for both a commercial cassette based synthesis system (AllinOne (AiO) system, Trasis, Belgium) and a research synthesis module with fixed tubing (RNplus, Synthra, Germany). The cleaning step involves a serial combination of several SPE cartridges. The synthesis time was shortened by 44% compared to synthesis using HPLC. At the same time the not decay corrected yield increases from 44 to 59% by using TBAHCO<sub>3</sub> as phase transfer catalysts and from 17 to 31% for the synthesis with K<sub>2</sub>CO<sub>3</sub>/Kryptofix-[2.2.2] compared to synthesis using HPLC. The Radiochemical purity was always > 98% and all quality control parameters (e.g. sterility, endotoxin, stability and Radiochemical purity) conformed with requirements of the European Pharmacopoeia.</p><h3>Conclusions</h3><p>A GMP compliant automatic synthesis of [<sup>18</sup>F]fallypride including purification using simple solid phase extraction cartridges instead of HPLC was developed and evaluated. The implementation of the simplified synthesis in both used commercial modules allows efficient and reproducible Radiosynthesis of [<sup>18</sup>F]fallypride and leads to short synthesis times and high radiochemical yields with high radiochemical purity.</p></div>","PeriodicalId":534,"journal":{"name":"EJNMMI Radiopharmacy and Chemistry","volume":"10 1","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ejnmmipharmchem.springeropen.com/counter/pdf/10.1186/s41181-025-00343-w","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143904751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号